Vanguard Group
SANA icon

Vanguard Group’s Sana Biotechnology SANA Stock Holding History

Vanguard Group’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$42.6M Buy
10,455,195
+1,326,222
+15% +$5.94M ﹤0.01% 2259
2025
Q3 		$32.4M Buy
9,128,973
+1,517,474
+20% +$5.49M ﹤0.01% 2383
2025
Q2 		$20.8M Sell
7,611,499
-253,882
-3% -$524K ﹤0.01% 2537
2025
Q1 		$13.2M Sell
7,865,381
-2,882,379
-27% -$8.06M ﹤0.01% 2695
2024
Q4 		$17.5M Sell
10,747,760
-2,435,792
-18% -$7.26M ﹤0.01% 2645
2024
Q3 		$54.8M Buy
13,183,552
+304,872
+2% +$1.6M ﹤0.01% 2136
2024
Q2 		$70.3M Buy
12,878,680
+723,507
+6% +$5.77M ﹤0.01% 2009
2024
Q1 		$122M Buy
12,155,173
+2,358,089
+24% +$17.7M ﹤0.01% 1764
2023
Q4 		$40M Buy
9,797,084
+629,499
+7% +$2.32M ﹤0.01% 2282
2023
Q3 		$35.5M Buy
9,167,585
+107,167
+1% +$576K ﹤0.01% 2293
2023
Q2 		$54M Sell
9,060,418
-25,514
-0.3% -$147K ﹤0.01% 2148
2023
Q1 		$29.7M Buy
9,085,932
+119,297
+1% +$477K ﹤0.01% 2417
2022
Q4 		$35.4M Buy
8,966,635
+126,754
+1% +$620K ﹤0.01% 2339
2022
Q3 		$53M Buy
8,839,881
+787,470
+10% +$5.68M ﹤0.01% 2152
2022
Q2 		$51.8M Buy
8,052,411
+382,729
+5% +$2.44M ﹤0.01% 2177
2022
Q1 		$63.4M Sell
7,669,682
-38,469
-0.5% -$311K ﹤0.01% 2186
2021
Q4 		$119M Buy
7,708,151
+119,607
+2% +$2.31M ﹤0.01% 1894
2021
Q3 		$171M Buy
7,588,544
+5,127,363
+208% +$108M ﹤0.01% 1696
2021
Q2 		$48.4M Buy
2,461,181
+133,574
+6% +$3.03M ﹤0.01% 2393
2021
Q1 		$77.9M Buy
+2,327,607
New +$75.8M ﹤0.01% 2085

Other funds holding SANA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Vanguard Group's SANA Position: Q4 2025 in Review

Vanguard Group increased its Sana Biotechnology (SANA) stake by 15% in Q4 2025, buying an estimated $5.94M and bringing the position to 10,455,195 shares worth $42.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2259.

Vanguard Group first reported a position in SANA in Q1 2021 and has held it in 20 quarters since. The position peaked at $171M in Q3 2021. 203 funds tracked by Wall St. Rank hold SANA as of Q4 2025.

  • Vanguard Group held 10,455,195 shares of Sana Biotechnology worth $42.6M as of Q4 2025.
  • Vanguard Group bought 1,326,222 Sana Biotechnology shares in Q4 2025, an estimated $5.94M.
  • Sana Biotechnology made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2259 holding.
  • Vanguard Group first reported a position in Sana Biotechnology in Q1 2021 and has held it in 20 quarters since.
  • Vanguard Group's Sana Biotechnology position peaked at $171M in Q3 2021.
  • 203 funds tracked by Wall St. Rank held Sana Biotechnology as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.